Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label, Single-arm Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous Hematopoietic Stem Cell Transplant for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)

NCT03432364 is registered in ClinicalTrials.gov with Sangamo Therapeutics as lead sponsor.

NCT NCT03432364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03432364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label, Single-arm Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous Hematopoietic Stem Cell Transplant for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
Lead sponsor
Sangamo Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
March 29, 2018
Completion date
November 17, 2022
Enrollment
5 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

transfusion dependent beta-thalassemia